Search

Your search keyword '"Abravanel, Florence"' showing total 693 results
Start Over Author "Abravanel, Florence"
693 results on '"Abravanel, Florence"'

51. Author Reply to Peer Reviews of A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals

Author

Joly, Etienne, primary, Izopet, Jacques, additional, Abravanel, Florence, additional, Volmer, Romain, additional, Schwartz, Olivier, additional, Robinot, Remy, additional, Bruel, Timothée, additional, Joly Featherstone, Eloïse, additional, Guéry, Jean Charles, additional, Bessière, Pierre, additional, and Ribes, Agnès Maurel, additional

Published
2022
Full Text
View/download PDF

52. Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine

Author

Abravanel, Florence, primary, Marion, Olivier, additional, Del Bello, Arnaud, additional, Beunon, Thomas, additional, Romieu-Mourez, Raphaelle, additional, Couat, Chloé, additional, Pucelle, Mélanie, additional, Staes, Laetitia, additional, Guitard, Joelle, additional, Esposito, Laure, additional, Faguer, Stanislas, additional, Kamar, Nassim, additional, and Izopet, Jacques, additional

Published
2022
Full Text
View/download PDF

53. Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load

Author

Migueres, Marion, primary, Dimeglio, Chloé, additional, Trémeaux, Pauline, additional, Raymond, Stéphanie, additional, Lhomme, Sébastien, additional, Da Silva, Isabelle, additional, Oliveira Mendes, Kévin, additional, Abravanel, Florence, additional, Félicé, Marie-Pierre, additional, Mansuy, Jean-Michel, additional, and Izopet, Jacques, additional

Published
2022
Full Text
View/download PDF

55. Hepatitis E virus infections in blood donors, France

Author

Gallian, Pierre, Lhomme, Sebastien, Piquet, Yves, Saune, Karine, Abravanel, Florence, Assal, Azzedine, Tiberghien, Pierre, and Izopet, Jacques

Subjects
Hepatitis E -- Health aspects, Biological products -- Health aspects, Infection -- Health aspects, RNA -- Health aspects, Immunoglobulin G -- Health aspects, Blood donors -- Health aspects, Health
Abstract

Hepatitis E virus (HEV), family Hepeviridae, genus Hepevirus, is a small nonenveloped RNA vims that has an icosahedral capsid and is transmitted by the fecaloral route (1). Transfusion-transmitted HEV infections [...]

Published
2014
Full Text
View/download PDF

59. Influence of Nasopharyngeal Viral Load on the Spread of the Omicron BA.2 Variant.

Author

Migueres, Marion, Dimeglio, Chloé, Mansuy, Jean-Michel, Abravanel, Florence, Raymond, Stéphanie, Latour, Justine, Jeanne, Nicolas, Ranger, Noémie, Lhomme, Sébastien, Saune, Karine, Tremeaux, Pauline, and Izopet, Jacques

Subjects
NASOPHARYNX microbiology, COVID-19, VIRAL load, DESCRIPTIVE statistics, POLYMERASE chain reaction, FRIEDMAN test (Statistics)
Abstract

We used variant typing polymerase chain reaction to describe the evolution of severe acute respiratory syndrome coronavirus 2 Omicron sublineages between December 2021 and mid-March 2022. The selective advantage of the BA.2 variant over BA.1 is not due to greater nasopharyngeal viral loads. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

62. A simple, sensitive and quantitative FACS-based test for SARS-CoV-2 serology in humans and animals

Author

Maurel Ribes, Agnès, Bessière, Pierre, Guéry, Jean Charles, Joly Featherstone, Eloïse, Bruel, Timothée, Robinot, Remy, schwartz, olivier, Abravanel, Florence, Izopet, Jacques, Joly, Etienne, Institut de pharmacologie et de biologie structurale (IPBS), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, and ANR-21-CO13-0004,HAT-FIELD,Validation du test HAT-COVID-19 comme test de terrain(2021)

Subjects
Foow cytometry, [SDV.BA.MVSA]Life Sciences [q-bio]/Animal biology/Veterinary medicine and animal Health, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, SARS-CoV-2, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV]Life Sciences [q-bio], [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, serodiagnostic, [SDV.IMM]Life Sciences [q-bio]/Immunology, hemagglutination, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Covid-19
Abstract

Serological tests are important for understanding the physiopathology and following the evolution of the Covid-19 pandemic. Assays based on flow cytometry (FACS) of tissue culture cells expressing the spike (S) protein of SARS-CoV-2 have repeatedly proven to perform slightly better than the plate-based assays ELISA and CLIA (chemiluminescent immuno-assay), and markedly better than lateral flow immuno-assays (LFIA). Here, we describe an optimized and very simple FACS assay based on staining a mix of two Jurkat cell lines, expressing either high levels of the S protein (Jurkat-S) or the mCherry fluorescent protein (Jurkat-R, which serve as an internal negative control). We show that this Jurkat-S&R-flow test has a much broader dynamic range than a commercial ELISA test and performs at least as well in terms of sensitivity and specificity. Also, it is more sensitive and quantitative than the hemagglutination-based test HAT, which we described recently. The Jurkat-R&S-flow test requires only a few microliters of blood; thus, it can be used to quantify various Ig isotypes in capillary blood collected from a finger prick. It can be used also to evaluate serological responses in mice, cats and dogs. FACS tests offer a very attractive solution for laboratories with access to tissue culture and flow cytometry who want to monitor serological responses in humans or in animals, and how these relate to susceptibility to infection, or reinfection, by the virus, and to protection against Covid-19.

Published
2021

63. Rat Hepatitis E Virus

Author

Parraud, Delphine, Lhomme, Sébastien, Péron, Jean Marie, da Silva, Isabelle, Tavitian, Suzanne, Kamar, Nassim, Izopet, Jacques, Abravanel, Florence, Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Benson-Rumiz, Alicia

Subjects
immunocompromised, South-Western France, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, rodent, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, hepatitis E, chronic hepatitis, zoonosis, rat hepatitis E virus, epatitis E virus, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background: Hepatitis E Virus (HEV) is one of the most common causes of hepatitis worldwide, and South-Western France is a high HEV seroprevalence area. While most cases of HEV infection are associated with the species Orthohepevirus-A, several studies have reported a few cases of HEV infections due to Orthohepevirus-C (HEV-C) that usually infects rats. Most of these human cases have occurred in immunocompromised patients. We have screened for the presence of HEV-C in our region. Methods and Results: We tested 224 sera, mostly from immunocompromised patients, for HEV-C RNA using an in-house real time RT-PCR. Liver function tests gave elevated results in 63% of patients: mean ALT was 159 IU/L (normal < 40 IU/L). Anti-HEV IgG (49%) and anti-HEV IgM (9.4%) were frequently present but none of the samples tested positive for HEV-C RNA. Conclusion: HEV-C does not circulate in the human population of South-Western France, despite the high seroprevalence of anti-HEV IgG.

Published
2021
Full Text
View/download PDF

75. Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly

Author

El Costa, Hicham, Gouilly, Jordi, Abravanel, Florence, Bahraoui, Elmostafa, Peron, Jean-Marie, Kamar, Nassim, Jabrane-Ferrat, Nabila, Izopet, Jacques, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], CHU Toulouse [Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire Virologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], and JABRANE-FERRAT, Nabila

Subjects
Male, Physiology, Pathogenesis, CD8-Positive T-Lymphocytes, Pathology and Laboratory Medicine, Infographics, MESH: Genotype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Immune Physiology, Cellular types, Biology (General), Immune Response, Data Management, MESH: Aged, Innate Immune System, Immune cells, MESH: Hepatitis E virus / genetics, Middle Aged, MESH: Case-Control Studies, Hepatitis E, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, [SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology, MESH: Hepatitis E / immunology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, White blood cells, Cytokines, Female, MESH: epatitis E / pathology, Graphs, MESH: Receptors, CXCR3 / metabolism, Research Article, Cell biology, Blood cells, Computer and Information Sciences, Receptors, CXCR3, Genotype, QH301-705.5, Immunology, T cells, Cytotoxic T cells, MESH: CD8-Positive T-Lymphocytes / immunology, Research and Analysis Methods, Signs and Symptoms, Hepatitis E virus, Humans, MESH: Hepatitis E virus / classification, Molecular Biology Techniques, Molecular Biology, Aged, Medicine and health sciences, Inflammation, Biology and life sciences, MESH: Immunologic Memory / immunology, Data Visualization, MESH: Cytokines / metabolism, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, RC581-607, Molecular Development, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Health Care, Animal cells, Immune System, Case-Control Studies, Geriatric Care, Immunologic diseases. Allergy, Clinical Medicine, Immunologic Memory, Developmental Biology, Cloning
Abstract

Genotype 3 Hepatitis E virus (HEV-3) is an emerging threat for aging population. More than one third of older infected patients develops clinical symptoms with severe liver damage, while others remain asymptomatic. The origin of this discrepancy is still elusive although HEV-3 pathogenesis appears to be immune-mediated. Therefore, we investigated the role of CD8 T cells in the outcome of the infection in immunocompetent elderly subjects. We enrolled twenty two HEV-3-infected patients displaying similar viral determinants and fifteen healthy donors. Among the infected group, sixteen patients experienced clinical symptoms related to liver disease while six remained asymptomatic. Here we report that symptomatic infection is characterized by an expansion of highly activated effector memory CD8 T (EM) cells, regardless of antigen specificity. This robust activation is associated with key features of early T cell exhaustion including a loss in polyfunctional type-1 cytokine production and partial commitment to type-2 cells. In addition, we show that bystander activation of EM cells seems to be dependent on the inflammatory cytokines IL-15 and IL-18, and is supported by an upregulation of the activating receptor NKG2D and an exuberant expression of T-Bet and T-Bet-regulated genes including granzyme B and CXCR3. We also show that the inflammatory chemokines CXCL9-10 are increased in symptomatic patients thereby fostering the recruitment of highly cytotoxic EM cells into the liver in a CXCR3-dependent manner. Finally, we find that the EM-biased immune response returns to homeostasis following viral clearance and disease resolution, further linking the EM cells response to viral burden. Conversely, asymptomatic patients are endowed with low-to-moderate EM cell response. In summary, our findings define immune correlates that contribute to HEV-3 pathogenesis and emphasize the central role of EM cells in governing the outcome of the infection., Author summary The outcome of Genotype 3 Hepatitis E virus (HEV-3) infection differs among the elderly. Some patients develop severe forms of Hepatitis E while others remain asymptomatic. Nonetheless, parameters which can lead to severe versus silent infection are largely unknown. Therefore, we investigated immunological features of CD8 T cells in infected patients (aged ≥55) with similar viral determinants but distinct clinical outcomes. We show that drastic phenotypic changes were specifically observed within the effector memory (EM) compartment. Compared to asymptomatic patients, symptomatic ones display a strong activation of both HEV-3-specific and -nonspecific EM CD8 T cells associated with qualitative and quantitative alterations in cytokine production. In addition, EM cells are endowed with high cytotoxic capacity and have the ability to rapidly migrate to the liver. Finally, we report that the inflammatory response to HEV-3 infection shape EM cell activation and function in symptomatic elderly patients. In summary, our results present the first report demonstrating that the nature and the magnitude of EM CD8 T cell response play an important role in the outcome of HEV-3 infection in the elderly.

Published
2021
Full Text
View/download PDF

76. An Evaluation of Hepatitis E Virus Molecular Typing Methods

Author

Baylis, Sally A., Adlhoch, Cornelia, Childs, Liam, Stühler, Anett, Karlsson, Marie, Molier, Michel, Suin, Vanessa, Lamoral, Sophie, Nasheri, Neda, Harlow, Jennifer, Rešetnjak, Irina, Abravanel, Florence, Lhomme, Sebastien, Izopet, Jacques, Pavio, Nicole, Pellerin, Marie, Eiden, Martin, Boettcher, Birke, Kaiser, Marco, Schilling-loeffler, Katja, Johne, Reimar, Schwarz, Tatjana, Corman, Victor M., Wenzel, Jürgen J., Klein, Jasmin, Bennett, Charlene, Degascun, Cillian, Dean, Jonathan, Ciccaglione, Anna Rita, Villano, Umbertina, Bruni, Roberto, Di Bartolo, Ilaria, De Sabato, Luca, La Rosa, Giuseppina, Ferraro, Giusy Bonanno, Mancini, Pamela, Suffredini, Elisabetta, Garbuglia, Anna Rosa, Boxman, Ingeborg, Dirks, René, Zwartkruis-nahuis, Ans, Hogema, Boris, De Sousa, Rita, Velebit, Branko, Avellón, Ana, Sánchez, Gloria, Cuevas-ferrando, Enric, Norder, Heléne, Bachofen, Claudia, Vonlanthen, Isabelle, Kubacki, Jakub, Lacher, David, Mammel, Mark, Kulka, Michael, Ministerio de Ciencia, Innovación y Universidades (España), Unión Europea. European Centre for Disease Prevention and Control (ECDC), Federal Ministry for Health (Alemania), Ministero della Salute (Italia), Dutch Food and Consumer Safety Authority, Ministerio de Ciencia e Innovación (España), Health Canada, and Abbott

Subjects
Genotype, Zika Virus Infection, genotype, Genotypes, Biochemistry (medical), Clinical Biochemistry, Subtype, hepatitis E virus, sequencing, Zika Virus, Hepatitis E, subtype, Molecular Typing, HEV, Voedsel en Waren Autoriteit, Hepatitis E virus, Sequencing, Humans, RNA, Viral, Team Virology & GMO, Ensure healthy lives and promote well-being for all at all ages, Phylogeny
Abstract

Hepatitis E virus (HEV) is a major cause of acute viral hepatitis. Better understanding of HEV subtypes involved in hepatitis E infections is essential. Investigation of sources and routes of transmission and the identification of potential clusters/outbreaks rely upon molecular typing of viral strains. A study was carried out to evaluate the ability of laboratories to undertake molecular typing with genotype and subtype determination., This work was supported by a service contract ECD.9621 from European Centre for Disease Prevention and Control. N. Nasheri and J. Harlow, Health Canada internal funds: Internal funding was used to perform viral detection and genotyping. K. Schilling-Loeffler, R. Johne, and V.M. Corman, grant of the German Federal Ministry of Health with regard to a decision of the German Bundestag by the Federal Government (CHED project grant no. ZMVI1-2518FSB705) to institution; G. La Rosa and E. Suffredini, Italian Ministry of Health; I.L.A. Boxman, R.A.M. Dirks, Dutch Food and Consumer Safety Authority; B. Hogema, Sanquin; A. Avellon, Diasorin Iberica, Abbott; G. Sanchez and E.C. Ferrando, MICIU project AGL2017-82909. The study was funded by ECDC with PEI receiving these funds to cover sample preparation, pre-testing and transport costs.

Published
2021

77. Hepatitis E virus strains in rabbits and evidence of a closely related strain in humans, France

Author

Izopet, Jacques, Dubois, Martine, Bertagnoli, Stephane, Lhomme, Sebastien, Marchandeau, Stephane, Boucher, Samuel, Kamar, Nassim, Abravanel, Florence, and Guerin, Jean-Luc

Subjects
Hepatitis E -- Genetic aspects -- Health aspects -- Analysis, Rabbits -- Health aspects -- Analysis, Infection -- Genetic aspects -- Health aspects -- Analysis, RNA -- Health aspects -- Analysis, Health
Abstract

Hepatitis E virus (HEV) is a major cause of acute hepatitis in many developing countries in Asia and Africa, where it is transmitted by the fecal-oral route because of poor [...]

Published
2012
Full Text
View/download PDF

78. Hepatitis E virus antibodies in blood donors, France

Author

Mansuy, Jean-Michel, Bendall, Richard, Legrand-Abravanel, Florence, Saune, Karine, Miedouge, Marcel, Ellis, Vic, Rech, Henri, Destruel, Francois, Kamar, Nassim, Dalton, Harry R., and Izopet, Jacques

Subjects
Hepatitis E -- Causes of -- Genetic aspects -- Research, Immunoglobulin G -- Health aspects -- Genetic aspects -- Research, Blood donors -- Health aspects, Health
Abstract

It is now recognized that hepatitis E virus infection is not confined to developing countries. HEV infection is a growing public health concern in industrialized countries where the disease is [...]

Published
2011
Full Text
View/download PDF

79. Hepatitis E virus seroprevalence and chronic infections in patients with HIV, Switzerland

Author

Kenfak-Foguena, Alain, Schoni-Affolter, Franziska, Burgisser, Philippe, Witteck, Andrea, Darling, Katharine E.A., Kovari, Helen, Kaiser, Laurent, Evison, John-Marc, Elzi, Luigia, La Fuente, Vanina Gurtner-De, Jost, Josef, Moradpour, Darius, Abravanel, Florence, Izopet, Jacques, and Cavassini, Matthias

Subjects
Transplantation of organs, tissues, etc. -- Health aspects, HIV (Viruses) -- Health aspects -- Care and treatment, Medical research -- Health aspects, Medicine, Experimental -- Health aspects, Hepatitis E -- Health aspects -- Care and treatment, HIV testing -- Health aspects, Prevalence studies (Epidemiology) -- Health aspects, Infection -- Health aspects -- Care and treatment, RNA -- Health aspects, Immunoglobulin G -- Health aspects, HIV infection -- Health aspects -- Care and treatment, Health
Abstract

Unexplained liver enzyme elevation is frequently encountered in HIV-infected persons (1). Hepatitis E virus (HEV) can cause deranged liver function. Chronic infection with HEV has been reported in patients with [...]

Published
2011
Full Text
View/download PDF

80. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France

Author

Legrand-Abravanel, Florence, Kamar, Nassim, Sandres-Saune, Karine, Lhomme, Sebastien, Mansuy, Jean-Michel, Muscari, Fabrice, Sallusto, Federico, Rostaing, Lionel, and Izopet, Jacques

Subjects
Hepatitis E -- Risk factors -- Analysis, Diseases -- Risk factors -- Analysis -- France, Azathioprine -- Analysis, Cytomegalovirus infections -- Risk factors -- Analysis, RNA -- Analysis, Tacrolimus -- Analysis, Immunoglobulin G -- Analysis, Kidney diseases -- Risk factors -- Analysis, Stem cells -- Transplantation, Liver cirrhosis -- Risk factors -- Analysis, Immunoglobulin M -- Analysis, Transplantation of organs, tissues, etc. -- Analysis, HIV (Viruses) -- Risk factors -- Analysis, Leukemia -- Risk factors -- Analysis, Immunotherapy -- Analysis, Enzymes -- Analysis, Donation of organs, tissues, etc. -- Analysis, Health
Abstract

Large epidemics of hepatitis E have occurred in Asia, Africa, and Latin America where sanitation is suboptimal (1). The numbers of non-travel-associated hepatitis E virus (HEV) infections have also increased [...]

Published
2011
Full Text
View/download PDF

83. Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

Author

Kamar, Nassim, Izopet, Jacques, Tripon, Simona, Bismuth, Michael, Hillaire, Sophie, Dumortier, Jérôme, Radenne, Sylvie, Coilly, Audrey, Garrigue, Valérie, DʼAlteroche, Louis, Buchler, Matthias, Couzi, Lionel, Lebray, Pascal, Dharancy, Sebastien, Minello, Anne, Hourmant, Maryvonne, Roque-Afonso, Anne-Marie, Abravanel, Florence, Pol, Stanislas, Rostaing, Lionel, and Mallet, Vincent

Published
2014
Full Text
View/download PDF

85. Hepatitis E virus genotype 3 diversity, France

Author

Legrand-Abravanel, Florence, Mansuy, Jean-Michel, Dubois, Martine, Kamar, Nassim, Peron, Jean-Marie, Rostaing, Lionel, and Izopet, Jacques

Subjects
Infection -- Health aspects, Infection -- Genetic aspects, Disease transmission -- Health aspects, Disease transmission -- Genetic aspects, Hepatitis E -- Health aspects, Hepatitis E -- Genetic aspects
Abstract

We characterized 42 hepatitis E virus (HEV) genotype 3 strains from infected patients in France in 3 parts of the genome and sequenced the full-length HEV genotype 3f genome found [...]

Published
2009

88. Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3

Author

Micas, Florence, primary, Suin, Vanessa, additional, Péron, Jean-Marie, additional, Scholtes, Caroline, additional, Tuaillon, Edouard, additional, Vanwolleghem, Thomas, additional, Bocket, Laurence, additional, Lhomme, Sébastien, additional, Dimeglio, Chloé, additional, Izopet, Jacques, additional, and Abravanel, Florence, additional

Published
2021
Full Text
View/download PDF

89. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept

Author

Chavarot, Nathalie, primary, Ouedrani, Amani, additional, Marion, Olivier, additional, Leruez-Ville, Marianne, additional, Vilain, Estelle, additional, Baaziz, Maroua, additional, Del Bello, Arnaud, additional, Burger, Carole, additional, Sberro-Soussan, Rebecca, additional, Martinez, Frank, additional, Chatenoud, Lucienne, additional, Abravanel, Florence, additional, Anglicheau, Dany, additional, Izopet, Jacques, additional, Couat, Chloé, additional, Zuber, Julien, additional, Legendre, Christophe, additional, Lanternier, Fanny, additional, Kamar, Nassim, additional, and Scemla, Anne, additional

Published
2021
Full Text
View/download PDF

90. Hepatitis E virus and chronic hepatitis in organ-transplant recipients

Author

Kamar, Nassim, Selves, Janick, Mansuy, Jean-Michel, Quezzani, Leila, Peron, Jean-Marie, Guitard, Joelle, Cointault, Olivier, Esposito, Laure, Abravanel, Florence, Danjoux, Marie, Durand, Dominique, Vinel, Jean-Pierre, Izopet, Jacques, and Rostaing, Lionel

Subjects
Hepatitis -- Causes of, Hepatitis -- Diagnosis, Hepatitis -- Patient outcomes, Hepatitis E virus -- Health aspects, Transplantation of organs, tissues, etc. -- Complications and side effects
Abstract

The Hepatitis E virus and its development into chronic hepatitis in patients having undergone organ transplants are discussed. It further states that further studies are required to investigate this incidence of Hepatitis E virus in transplant patients living in areas where this disease is not common.

Published
2008

91. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation

Author

Kamar, Nassim, Legrand-Abravanel, Florence, Behrendt, Patrick, Hofmann, Jörg, Pageaux, Georges Phillippe, Barbet, Christelle, Moal, Valerie, Couzi, Lionel, Horvatits, Thomas, de Man, Robert, Cassuto, Elisabeth, Elsharkawy, Ahmed, Riezebos-Brilman, Annelies, Scemla, Anne, Hillaire, Sophie, Donnelly, Mhairi, Radenne, Sylvie, Sayegh, Johnny, Garrouste, Cyril, Dumortier, Jérôme, Glowaki, François, Matignon, Marie, Coilly, Audrey, Figueres, Lucile, Mousson, Christiane, Minello, Anne, Dharancy, Sébastien, Rerolle, Jean Philippe, Lebray, Pascal, Etienne, Isabelle, Perrin, Peggy, Choi, Mira, Olivier, Marion, Izopet, Jacques, Bellière, J, Cointault, O., del Bello, Arnaud, Espostio, L, Hebral, A, Lavayssière, L, Lhomme, S, Mansuy, J, Wedemeyer, H, Nickel, P, Bismuth, M., Stefic, K, Buchler, M., D’alteroche, L, Colson, P., Bufton, S, Ramière, C, Trimoulet, P., Pischke, S, Todesco, E, Sberro Soussan, R, Legendre, C, Mallet, V., Johannessen, I, Simpson, K, Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Toulouse [Toulouse], Université Fédérale Toulouse Midi-Pyrénées, Hannover Medical School [Hannover] (MHH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Marseille (APHM), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), CHU Bordeaux [Bordeaux], Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre Hospitalier Universitaire de Nice (CHU Nice), University Hospitals Birmingham [Birmingham, Royaume-Uni], University Medical Center Groningen [Groningen] (UMCG), Réseau CENTAURE, Hôpital Foch [Suresnes], Royal Infirmary of Edinburgh, Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Clermont-Ferrand, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Paul Brousse, Centre hospitalier universitaire de Nantes (CHU Nantes), Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Hôpital Claude Huriez [Lille], CHU Lille, Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Rouen, Normandie Université (NU), CHU Strasbourg, Département de Néphrologie et Transplantation d'organes [Toulouse], Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Gastroenterology & Hepatology, CHU Toulouse [Toulouse]-Hôpital de Rangueil, Université de Montpellier (UM)-CHU Saint-Eloi, Service de néphrologie et immunologie clinique [CHRU Tours] (EA4245 UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours, Département de Néphrologie et Transplantation d'organes, Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service de néphrologie et immunologie clinique, Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10

Subjects
0301 basic medicine, MESH: Antiviral Agents / therapeutic use, Sofosbuvir, viruses, medicine.disease_cause, Gastroenterology, THERAPY, Organ transplantation, Hepatitis E virus / genetics, Hepatitis E / drug therapy, Humans, chemistry.chemical_compound, 0302 clinical medicine, Hepatitis E virus, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, MUTATION, MESH: Hepatitis E* / drug therapy, POLYMERASE, organ transplantation, virus diseases, MESH: Ribavirin / therapeutic use, Anemia, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Hepatitis E, anemia, 3. Good health, PREDICTS, Sustained virological response, Infectious Diseases, MESH: RNA, Viral, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, 030211 gastroenterology & hepatology, sustained virological response, medicine.drug, Microbiology (medical), medicine.medical_specialty, ribavirin, MESH: Organ Transplantation / adverse effects, RNA, Viral Retrospective Studies, Ribavirin / therapeutic use, Alpha interferon, MESH: Organ Transplantation* / adverse effects, hepatitis E virus, Antiviral Agents, Virus, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Ribavirin, Retrospective Studies, MESH: Hepatitis E virus* / genetics, MESH: Humans, business.industry, Retrospective cohort study, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, IN-VITRO, medicine.disease, digestive system diseases, 030104 developmental biology, chemistry, SOFOSBUVIR, HEV, REPLICATION, INTERFERON-ALPHA, business
Abstract

Background Ribavirin is currently recommended for treating chronic hepatitis E virus (HEV) infection. This retrospective European multicenter study aimed to assess the sustained virological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factors for SVR, and to evaluate the impact of HEV RNA mutations on virological response. Methods Data from 255 SOT recipients with chronic HEV infection from 30 European centers were analyzed. Ribavirin was given at the median dose of 600 (range, 29–1200) mg/day (mean, 8.6 ± 3.6 mg/kg/day) for a median duration of 3 (range, 0.25–18) months. Results After a first course of ribavirin, the SVR rate was 81.2%. It increased to 89.8% when some patients were offered a second course of ribavirin. An increased lymphocyte count at the initiation of therapy was a predictive factor for SVR, while poor hematological tolerance of ribavirin requiring its dose reduction (28%) and blood transfusion (15.7%) were associated with more relapse after ribavirin cessation. Pretreatment HEV polymerase mutations and de novo mutations under ribavirin did not have a negative impact on HEV clearance. Anemia was the main adverse event. Conclusions This large-scale retrospective study confirms that ribavirin is highly efficient for treating chronic HEV infection in SOT recipients and shows that the predominant HEV RNA polymerase mutations found in this study do not affect the rate of HEV clearance. This large-scale retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that HEV RNA polymerase mutations do not play a role in HEV clearance.

Published
2020
Full Text
View/download PDF

92. Hepatitis E Virus: How It Escapes Host Innate Immunity

Author

Lhomme, Sébastien, Migueres, Marion, Abravanel, Florence, Olivier, Marion, Kamar, Nassim, Izopet, Jacques, PINIER, CHRISTINE, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, viruses, immune escape, innate immune response, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, virus diseases, hepatitis E virus
Abstract

International audience; Hepatitis E virus (HEV) is a leading cause of viral hepatitis in the world. It is usually responsible for acute hepatitis, but can lead to a chronic infection in immunocompromised patients. The host's innate immune response is the first line of defense against a virus infection; there is growing evidence that HEV RNA is recognized by toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), leading to interferon (IFN) production. The IFNs activate interferon-stimulated genes (ISGs) to limit HEV replication and spread. HEV has developed strategies to counteract this antiviral response, by limiting IFN induction and signaling. This review summarizes the advances in our knowledge of intracellular pathogen recognition, interferon and inflammatory response, and the role of virus protein in immune evasion.

Published
2020
Full Text
View/download PDF

94. Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes

Author

Nicot, Florence, primary, Dimeglio, Chloé, additional, Migueres, Marion, additional, Jeanne, Nicolas, additional, Latour, Justine, additional, Abravanel, Florence, additional, Ranger, Noémie, additional, Harter, Agnès, additional, Dubois, Martine, additional, Lameiras, Sonia, additional, Baulande, Sylvain, additional, Chapuy-Regaud, Sabine, additional, Kamar, Nassim, additional, Lhomme, Sébastien, additional, and Izopet, Jacques, additional

Published
2021
Full Text
View/download PDF

100. Risk for Hepatitis E Virus Transmission by Solvent/Detergent–Treated Plasma

Author

Gallian, Pierre, primary, Lhomme, Sébastien, additional, Morel, Pascal, additional, Gross, Sylvie, additional, Mantovani, Carole, additional, Hauser, Lisette, additional, Tinard, Xavier, additional, Pouchol, Elodie, additional, Djoudi, Rachid, additional, Assal, Azzedine, additional, Abravanel, Florence, additional, Izopet, Jacques, additional, and Tiberghien, Pierre, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results